United Therapeutics Corporation (UTHR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

184.57-1.22 (-0.66%)

At close: 4:00PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	185.79
Open	185.92
Bid	184.46 x 900
Ask	229.90 x 1000
Day's Range	184.24 - 187.90
52 Week Range	98.37 - 212.62
Volume	182,870
Avg. Volume	311,046

Market Cap	8.268B
Beta (5Y Monthly)	0.49
PE Ratio (TTM)	20.57
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-16% Est. Return

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

PR Newswire
United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study
United Therapeutics Corporation (Nasdaq: UTHR) today announced the publication in The Lancet Respiratory Medicine of a post-hoc analysis of forced vital capacity (FVC) change in patients during the INCREASE study of Tyvaso® (treprostinil) Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3 pulmonary hypertension).
PR Newswire
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA
MannKind Corporation (Nasdaq: MNKD) and United Therapeutics Corporation (Nasdaq: UTHR) reached a major milestone today with the announcement that the U.S. Food and Drug Administration (FDA) accepted for priority review of the New Drug Application (NDA) for Tyvaso DPI™ (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The development marks the second compound formulated with MannKind's T
PR Newswire
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review
United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the New Drug Application (NDA) for Tyvaso DPI™ (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency's review to be complete in October 2021. FDA also indicated that they have not identified any potential review i